Al Bandar Mahdi Hussain, Kim Nam Kyu
Department of Surgery, Yonsei University, College of Medicine, Seoul 120-752, Republic of Korea.
Oncol Rep. 2017 May;37(5):2553-2564. doi: 10.3892/or.2017.5531. Epub 2017 Mar 27.
Liver metastasis is the most common site of colorectal cancer (CRC) metastasis. Approximately half of all colorectal cancer patients will develop liver metastases. Although radical surgery is the standard treatment modality, only 10-20% of patients are deemed eligible for resection. Despite advances in survival with chemotherapy, surgical resection is still considered the only curative option for patients with liver metastases. Much effort has been expended to address patients with metastatic liver disease. The majority of evidence stated a significant survival benefit with surgical resection to reach an overall 5-year survival rate of 35-55% after hepatic resection. However, still majority of patients will experience disease recurrence even after a successful resection. In this review, we describe current status and controversies related to treatment options for CRC liver metastases and its potential for enhancing oncologic outcomes and improving quality of life.
肝转移是结直肠癌（CRC）最常见的转移部位。所有结直肠癌患者中约有一半会发生肝转移。尽管根治性手术是标准的治疗方式，但只有10%-20%的患者被认为适合进行切除。尽管化疗使生存率有所提高，但手术切除仍然被认为是肝转移患者唯一的治愈选择。人们已经付出了很多努力来治疗肝转移患者。大多数证据表明，手术切除能带来显著的生存获益，肝切除术后总体5年生存率可达35%-55%。然而，即使手术成功切除，仍有大多数患者会出现疾病复发。在本综述中，我们描述了结直肠癌肝转移治疗方案的现状和争议，以及其在提高肿瘤治疗效果和改善生活质量方面的潜力。
